Ascending Dose, Placebo Controlled Comparative Study of SJP-0130 in Healthy Japanese Subjects

SJP-0130 Phase I -A Randomized, Double-Masked, Placebo Controlled Parallel Group, Single Center, Ascending Dose Study in Healthy Japanese Adult Male Subjects-

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051200086

Enrollment

Registered

2020-11-23

Start date

2020-11-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Administration of SJP-0130 or placebo and blood collection

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Healthy Japanese male - 20-35 years of age at the time of the informed consent - Other protocol-specified inclusion criteria may apply

Exclusion criteria

Exclusion criteria: - History of severe systemic or mental illness - History of allergy symptoms - Judged by the investigator as being ineligible - Other protocol-specified exclusion criteria may apply

Design outcomes

Primary

Measure	Time frame
Safety and tolerability (adverse events etc.), pharmacokinetics	—

Contacts

Public ContactClinical development division

Senju Pharmaceutical Co., Ltd.

senju-clinicaltrials@senju.co.jp+81-78-777-1018

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026